Copenhagen - Delayed Quote DKK

Novo Nordisk A/S (NOVO-B.CO)

476.70

+10.35

+(2.22%)

At close: June 4 at 4:59:31 PM GMT+2

1 Underrated Reason to Buy This Market-Beating Stock

Eli Lilly recently acquired a smaller biotech for its promising investigational pain medication. The company generates strong sales from products outside of diabetes and obesity care. Eli Lilly's portfolio, both within and outside its core area, makes the stock attractive.

Motley Fool 20 hours ago

LLY

NVO
Why Novo Nordisk (NVO) is a Top Dividend Stock for Your Portfolio

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novo Nordisk (NVO) have what it takes? Let's find out.

Zacks 2 days ago

NVO
Weight Loss Drug ETF (THNR) Hits New 52-Week High

THNR hits a 52-week high, fueled by gains in Eli Lilly and Novo Nordisk -- could the rally still have legs?

Zacks 2 days ago

LLY

NVO
Hims to cut 4% of workforce amid ban on weight-loss drug copies

NEW YORK (Reuters) -Telehealth platform Hims & Hers will cut 68 employees, or about 4% of its workforce, as it adjusts to a U.S. ban on manufacturing mass copies of the weight-loss drug Wegovy. A U.S. Food and Drug Administration ban on compounded copies of Wegovy, made by Novo Nordisk, took effect on May 22. Hims did not provide details about the roles that were cut, but said they were implemented across teams.

Reuters 5 days ago

NVO
2 Top Stocks to Buy With Less Than $100

Novo Nordisk should perform well thanks to new leadership and a strong underlying business. Exelixis' main oncology franchise is safe for now even as it seeks to develop newer products. When investing on a budget, buying fractional shares of top companies is one option.

Motley Fool 5 days ago

NVO

EXEL
2 Beaten-Down Stocks to Buy on the Dip

Novo Nordisk has strengths, including a deep pipeline, that should help it overcome recent obstacles. Cava Group's results are excellent, and in the long run the restaurant chain still has strong potential. Novo Nordisk (NYSE: NVO) and Cava Group (NYSE: CAVA) are excellent choices.

Motley Fool 5 days ago

NVO

CAVA
How Ozempic maker Novo Nordisk fell behind Eli Lilly in the weight loss drug race

Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant consistently led the pack in new prescriptions, becoming virtually synonymous with a booming weight loss drug market that could hit $139 billion by 2030.

Quartz 5 days ago

NVO

LLY
Was Jim Cramer Right About Eli Lilly and Company (LLY)?

We recently published a list of Did Jim Cramer Nail or Miss These 11 Stock Predictions? In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other stocks that Jim Cramer discusses. In that episode, a caller asked about Eli Lilly and Company (NYSE:LLY), particularly in […]

Insider Monkey 6 days ago

LLY

NVO
Meet the New Group of Weight-Loss Drugs. The Industry Is Betting Big on Amylin.

Amylin seems to be easier on the gut than GLP-1s like Ozempic, though it may produce less weight loss.

Barrons.com 6 days ago

NVO
Novo Nordisk Is Shedding Muscle In The Weight-Loss Brawl With Eli Lilly

Novo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.

Investor's Business Daily 6 days ago

LLY

NONOF

NVO
How Ozempic’s Maker Lost Its Grip on the Obesity Market It Created

Novo Nordisk’s weight-loss drug Wegovy has been surpassed in weekly U.S. prescriptions by Eli Lilly’s Zepbound, and now the company is trying to get back on track.

The Wall Street Journal 7 days ago

LLY

NONOF

NVO
GLP-1 prescriptions for weight loss are shooting up, despite obstacles

The percentage of overweight or obese adults prescribed GLP-1s jumped by almost 587% between 2019 and 2024, according to a new Fair Health report.

Healthcare Dive 7 days ago

NVO
Novo Nordisk's 52% Plunge: Is the Company Fumbling Its Leadership in the $150 Billion Weight Loss Market?

Ozempic helped Novo Nordisk gain an early lead in the weight loss industry, but competition is nipping at the company's heels.

Motley Fool 7 days ago

NVO
Jim Cramer Notes Eli Lilly (LLY) Stock is at a “Decent Level to Start a Position”

We recently published a list of Jim Cramer Had These 21 Stocks on His Radar. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other stocks that Jim Cramer discusses. A caller asked what Cramer’s thoughts on Eli Lilly and Company (NYSE:LLY) were, and he […]

Insider Monkey 8 days ago

LLY

NVO
Novo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock Has More Upside?

With VKTX surging on clinical results and NVO investing to cement market share, investors face a high-stake GLP-1 showdown.

Zacks 8 days ago

NVO

VKTX
3 Surprising Stocks That Have More Than Doubled in 2025

Just 14 stocks with market caps above $1 billion have doubled so far this year. They probably aren't the winners you would have predicted.

Motley Fool 8 days ago

DIS

FUBO

GRPN
Why Novo Nordisk Stock Just Popped

President Trump has good news for Novo Nordisk investors, and more may be on the way.

Motley Fool 8 days ago

NVO
Prothena's Late-Stage Study for AL Amyloidosis Fails, Stock Down

PRTA shares drop 22% after ending birtamimab development as a phase III study fails to meet primary or secondary endpoints in AL amyloidosis.

Zacks 8 days ago

PRTA

ROG.SW

NVO
Here is What to Know Beyond Why Novo Nordisk A/S (NVO) is a Trending Stock

Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.

Zacks 9 days ago

NVO
Why Hims & Hers Health Stock (HIMS) Is Too Hot to Handle

Hims & Hers Health (HIMS) has captured significant market attention in 2025 with its dramatic stock swings, starting the year around $25, soaring above $70, dipping back near $25, and now rebounding past $52. Despite the volatility, the stock is up over 120% year-to-date, ranking it among the best-performing mid- to large-cap names, with a market valuation exceeding $13 billion. So, what’s behind this massive surge in value? Hims’ unmatched ability to capitalize on the booming demand for GLP-1 d

TipRanks 11 days ago

HIMS

NONOF

NVO

Performance Overview

Return	NOVO-B.CO	OMX Copenhagen 25 Index (^OMXC25)
YTD	-22.35%	-0.88%
1-Year	-48.03%	-10.85%
3-Year	+28.07%	+5.05%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Novo Nordisk A/S (NOVO-B.CO)

1 Underrated Reason to Buy This Market-Beating Stock

Why Novo Nordisk (NVO) is a Top Dividend Stock for Your Portfolio

Weight Loss Drug ETF (THNR) Hits New 52-Week High

Hims to cut 4% of workforce amid ban on weight-loss drug copies

2 Top Stocks to Buy With Less Than $100

2 Beaten-Down Stocks to Buy on the Dip

How Ozempic maker Novo Nordisk fell behind Eli Lilly in the weight loss drug race

Was Jim Cramer Right About Eli Lilly and Company (LLY)?

Meet the New Group of Weight-Loss Drugs. The Industry Is Betting Big on Amylin.

Novo Nordisk Is Shedding Muscle In The Weight-Loss Brawl With Eli Lilly

How Ozempic’s Maker Lost Its Grip on the Obesity Market It Created

GLP-1 prescriptions for weight loss are shooting up, despite obstacles

Novo Nordisk's 52% Plunge: Is the Company Fumbling Its Leadership in the $150 Billion Weight Loss Market?

Jim Cramer Notes Eli Lilly (LLY) Stock is at a “Decent Level to Start a Position”

Novo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock Has More Upside?

3 Surprising Stocks That Have More Than Doubled in 2025

Why Novo Nordisk Stock Just Popped

Prothena's Late-Stage Study for AL Amyloidosis Fails, Stock Down

Here is What to Know Beyond Why Novo Nordisk A/S (NVO) is a Trending Stock

Why Hims & Hers Health Stock (HIMS) Is Too Hot to Handle

Performance Overview